Phosphodiesterase 5 Mechanisms and Therapeutic Applications
Open Access
- 22 July 2005
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 96 (12) , 29-31
- https://doi.org/10.1016/j.amjcard.2005.07.008
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP StimulationMolecular Pharmacology, 2004
- Novel nitric oxide signaling mechanisms regulate the erectile responseInternational Journal Of Impotence Research, 2004
- Mechanisms of action of PDE5 inhibition in erectile dysfunctionInternational Journal Of Impotence Research, 2004
- Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profilesClinical Cardiology, 2004
- Cyclic nucleotide phosphodiesterases: Relating structure and functionPublished by Elsevier ,2004
- Overview of phosphodiesterase 5 inhibition in erectile dysfunctionPublished by Elsevier ,2003
- Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation surveyInternational Journal Of Impotence Research, 2003
- Structure of the catalytic domain of human phosphodiesterase 5 with bound drug moleculesNature, 2003
- Individual Cerebellar Purkinje Cells Express Different cGMP Phosphodiesterases (PDEs):In VivoPhosphorylation of cGMP-Specific PDE (PDE5) as an Indicator of cGMP-dependent protein kinase (PKG) ActivationJournal of Neuroscience, 2003
- Erectile DysfunctionNew England Journal of Medicine, 2000